ONCObind™ Extracorporeal Procedure for Metastatic Cancer

Opportunities & Challenges in Metastatic Cancer

“Metastasis is the hallmark of cancer that is responsible for the greatest number of cancer-related deaths.”¹ It is estimated that more than 600,000 patients in the United States will die from cancer in 2022², of which 90% will be from metastatic causes.³

Metastatic cancer lacks effective therapies as it is often resistant to chemotherapy, radiation, and immunotherapy. A higher concentration of circulating tumor cells (CTCs) in blood is associated with unfavorable outcomes in metastatic cancer.⁴

Experimental methods which remove CTCs have been shown to improve outcomes in animals.⁵ Reduction of CTCs from the bloodstream may provide patient benefit by slowing or preventing metastasis.⁶

Circulating Tumor Cell Removal Program

ONCObind Procedure for Circulating Tumor Cell Removal
The ONCObind Extracorporeal Blood Filter has demonstrated in vitro adsorption of circulating tumor cells (CTCs) from plasma, sparking accelerated clinical research activity in the area of oncology.⁷

• FDA has granted Investigational Device Exemption (IDE) for the ONCObind Procedure, allowing study in patients suffering from metastatic pancreatic ductal adenocarcinoma (PDAC)

• Greater than 96% single-pass removal of CTC’s observed in vitro⁷

• In vitro results replicated at multiple investigational sites

Publications

Shishido SN, Suresh D et al. Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy. BJC Rep 2, 47 (2024). doi: 10.1038/s44276-024-00069-3